Reports on Data Presented at AHA
TORONTO, Nov. 16 /CNW/ - Novadaq(R) Technologies Inc. (TSX: NDQ)
announces data published in the Journal of the American College of Cardiology
(JACC) and research findings for a heart bypass drug trial in the Journal of
the American Medical Association (JAMA).
Results from a prospective trial using Novadaq's SPY(R) Intra-Operative
Imaging System, published in the October 18 issue of the JACC, suggests a
significant number of graft failures can be identified in the operating room.
"An under appreciated number of bypass grafts have failed in the operating
room and these failed grafts lead to poorer outcomes for the patient," said
Dr. Nimesh Desai of Sunnybrook and Women's College Health Science Center in
Toronto, Canada.
Research findings from the Prevent IV heart bypass drug trial were also
released today in the Journal of the American Medical Association (JAMA), and
presented during the American Heart Association's Annual Scientific Sessions
earlier this week. While the national study of 3,014 patients concluded the
drug edifoligide was not effective in preventing bypass vein failure,
researchers did identify up to thirty percent of vein grafts used in heart
bypass surgery fail at one year, marking a significant increase above earlier
scientific estimates of five to thirteen percent.
Heart experts acknowledge the benefits of bypass surgery for
appropriately selected patients, and understand the need for further research
to determine the factors of failure and durability in vein grafts.
Consequences of graft failure include repeat chest pain, revascularization
procedures and death. Technology to assess bypass grafts during surgery, such
as the SPY System, is an important advancement in cardiac surgery.
Leading cardiac surgeons and researchers collaborated with the medical
industry to develop the SPY Intra-Operative Imaging System, the first and only
fluorescent imaging system available for use during heart bypass surgery.
Doctors predict widespread adoption of intra-operative imaging will
significantly reduce unrecognized graft failures, helping to decrease
complications and repeat surgeries.
For years, heart experts have made educated estimates about the
percentage of failed bypasses, because X-ray angiography, the current gold
standard for assessing coronary arteries, is not considered practical for the
operating room, due in part to safety risks. The result is that patient's
bypass grafts have not been routinely assessed during the operation.
Dr. Michael Mack, a cardiac surgeon and investigator in the Prevent IV
trial, participated in early research and development of the SPY System. "We
have been searching for a more definitive way to confirm the quality of the
bypasses placed on the heart," said Dr. Mack of Medical City Hospital in
Dallas, Texas. "Now, surgeons can make necessary adjustments during a
procedure, based on real-time images."
Dr. Mercedes K.C. Dullum, cardiac surgeon at Cleveland Clinic Florida and
user of the SPY System added that "This is an emerging technology that now
allows us to assess our grafts intra-operatively and is a significant
advancement in helping surgeons improve the quality of bypass surgery."
In 2005 over 400,000 bypass surgeries are likely to be performed in the
United States alone. The SPY System is practical for use in both traditional
on-pump coronary artery bypass procedures, where the patient's heart is
stopped and blood is pumped through the body via a heart-lung machine, and
off-pump coronary artery bypass procedures, where the heart is not stopped.
About Novadaq Technologies
Novadaq Technologies (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY Intra-operative Imaging System enables surgeons to visually assess
coronary vasculature and bypass graft functionality during the course of
cardiac surgery. Novadaq's ophthalmic product, the OPTTX System, is aimed at
the diagnosis, evaluation and treatment of wet Age-related Macular
Degeneration (AMD) by using the same core imaging technology that is used in
the SPY System. The OPTTX System is currently being evaluated in clinical
trials.
For more information, please visit the company's website at
www.novadaq.com.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
%SEDAR: 00022069E
Novadaq Announces Data Published in the JACC
Novadaq Technologies Inc. on 6ix
Earlier from Novadaq Technologies
- Novadaq reports financial results for third quarter of 2005
- Ammended conference call notice
- Novadaq to hold third quarter 2005 conference call and webcast
- Novadaq Adds Co-Chief Medical Advisors to Cardiac Team
- Novadaq Establishes United States Subsidiary Achieves September's SPY Placement Goal
Later from Novadaq Technologies
- Novadaq's SPY System highlighted at STS' Annual Meeting Symposium
- Novadaq Obtains Exclusive Nerve Imaging IP
- Novadaq to hold fiscal 2005 year-end and fourth quarter results conference call and webcast
- Novadaq Receives Frost & Sullivan Award of Excellence
- Novadaq reports fiscal 2005 year-end and fourth quarter results
Follow Novadaq Technologies into a list and get an email when it puts out news.
Follow Novadaq Technologies